SpectraWAVE, a medical imaging company focused on enhancing the treatment and outcomes for patients with coronary artery disease (CAD), has raised $50m in a Series B funding round.
Johnson & Johnson Innovation – JJDC led the round. The Series B round also saw the participation of S3 Ventures, Lumira Ventures, Deerfield Management, SV Health Investors, Heartwork Capital, NovaVenture, and other undisclosed investors.
This investment will help SpectraWAVE expand its commercial presence and add new products for its HyperVue Imaging System. The system is designed to support interventionalists in making and optimising treatment decisions.
HyperVue is used for imaging coronary arteries and is suitable for patients undergoing transluminal interventional procedures. It received US Food and Drug Administration (FDA) clearance in March 2023.
According to SpectraWAVE, HyperVue is the first intravascular imaging technology to integrate DeepOCT and near infrared spectroscopy (NIRS) imaging methods. Its workflows are optimised for the cardiac catheterisation lab.
The system’s NIRS capability helps identify patients and plaques at higher risk for major adverse cardiac events.
Features include no-flush catheter preparation, rapid and extended pullbacks to minimise contrast use, and an advanced artificial intelligence (AI)-driven workflow with comprehensive image analysis.
SpectraWAVE CEO Eman Namati said: “This evidence and broad recognition of impact has recently moved intravascular imaging to a 1A guideline recommendation in Europe, with an expectation that the US will follow in due time.
“Increasing both the capabilities and the ease of use of intravascular imaging systems is now critical to expand the use of imaging and improve care for these patients.
“That is our mission with HyperVue – simpler, faster, and better imaging to drive optimised stenting procedures for improved patient outcomes.
“The reception to the product during our initial US launch has been fantastic, and this financing, supported by leading MedTech investors, will support our commercial expansion to bring HyperVue to more patients.”
In September 2023, the medical imaging company secured FDA 510(k) clearance for product enhancements to the HyperVue Imaging System.
The product enhancements for the system include contrast-free saline imaging, advanced AI algorithms for identifying clinical structures and hands-free angiographic co-registration.
These updates build on the existing HyperVue toolkit, which features AI-driven detection of lipids, lumen, stents, and side branches.
